Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Docetaxel (DB01248)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2 IdentifierTitlePurposeDrugs
NCT03517969M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerTreatment
NCT02516670Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate CancerTreatment
NCT02985021Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair DeficienciesTreatment
NCT04028388ModraDoc006/r vs Docetaxel IV in Metastatic Prostate CancerTreatment
NCT03951831REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate CancerTreatment
NCT03764540Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideTreatment